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Abstract
Background: Late onset neonatal sepsis (LOS) with the mortality of 17 to 27% is still a serious disease. Meropenem
is an antibiotic with wide antibacterial coverage. The advantage of it over standard of care could be its wider
antibacterial coverage and thus the use of mono-instead of combination therapy.
Methods: NeoMero-1, an open label, randomised, comparator controlled, superiority trial aims to compare the
efficacy of meropenem with a predefined standard of care (ampicillin + gentamicin or cefotaxime + gentamicin) in
the treatment of LOS in neonates and infants aged less than 90 days admitted to a neonatal intensive care unit.
A total of 550 subjects will be recruited following a 1:1 randomisation scheme. The trial includes patients with
culture confirmed (at least one positive culture from normally sterile site except coagulase negative staphylococci
in addition to one clinical or laboratory criterion) or clinical sepsis (at least two laboratory and two clinical criteria
suggestive of LOS in subjects with postmenstrual age < 44 weeks or fulfilment of criteria established by the
International Pediatric Sepsis Consensus Conference in subjects with postmenstrual age ≥ 44 weeks). Meropenem
will be given at a dose of 20 mg/kg q12h or q8h depending on the gestational- and postnatal age. Comparator
agents are administered as indicated in British National Formulary for Children. The primary endpoint measured at
the test of cure visit (2 days after end of study therapy) is graded to success (all baseline symptoms and laboratory
parameters are resolved or improved with no need to continue antibiotics and the baseline microorganisms are
eradicated and no new microorganisms are identified and the patient has received allocated treatment for 11 ± 3
days with no modification) or a failure (all remaining cases). Secondary outcome measures include comparison of
survival, relapse rates or new infections by Day 28, clinical response at Day 3 and end of therapy, duration of
hospitalisation, population pharmacokinetic analysis of meropenem and effect of antibiotics on mucosal
colonisation and development of antibacterial resistance.
The study will start recruitment in September 2011; the total duration is of 24 months.
Trial registration: EudraCT 2011-001515-31
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Background
A recent review including eight studies conducted in
European and Australian neonatal wards showed that 80
to 93% of prescriptions are for off-label or unlicensed
products [1]. In its 7th framework programme the
European Union has funded several projects that specifi-
cally aim to evaluate pharmacokinetics (PK), efficacy
and safety of off-patent medicines in children. One pro-
ject funded in 2010 is NeoMero-1, an open label, rando-
mised, controlled superiority trial that aims to compare
the efficacy of meropenem with a predefined standard
of care (SOC) for the treatment of late onset sepsis
(LOS) in neonates and infants aged less than 90 days
(inclusive) admitted to a neonatal intensive care unit
(NICU). The safety of study regimens as well as LOS-
causing microorganisms and their antibiotic susceptibil-
ity patterns, bacterial eradication-, relapse- and superin-
fection rates, mucosal colonisation with antibiotic
resistant microorganisms and fungi, genetic markers
that may affect response to therapy and the PK charac-
teristics of meropenem will be described as secondary
outcome measures.
Late onset sepsis
LOS is commonly defined as sepsis occurring 48 to
72 hours after birth, and is a serious disease with a mortal-
ity rate of 17% to 27% depending on the studied popula-
tion [2-5]. Although LOS is predominantly caused by
coagulase negative staphylococci (CoNS) accounting for
36-66% of cases [3,4,6-8], Gram-negative rods Klebsiella
pneumoniae, Escherichia coli, Serratia spp and Enterobac-
ter cloacae are responsible for about 26-36% of cases
[4,6,9]. In recent years the incidence of Gram negative
infections appears to be increasing in many NICUs world-
wide [10-12]. In an UK based microbiology laboratory sur-
vey, after exclusion of CoNS, the majority of LOS isolates
were susceptible to the commonly used combinations of
empiric antibiotics flucloxacillin, gentamicin, ampicillin
and/or cefotaxime, however, relatively high resistance
rates of Enterobacteriaceae to cephalosporins were
reported [3,13].
Use of meropenem in neonates
Meropenem is a low protein-bound (2%) broad-spectrum
carbapenem with the bactericidal activity resulting from
inhibition of bacterial peptidoglycan synthesis in the cell
wall. It is active against Gram-positive and Gram-negative
bacteria including anaerobes and extended spectrum beta-
lactamase and AmpC chromosomal b-lactamase produ-
cing Enterobacteriaceae [14]. The pharmacodynamics
(PD) of meropenem is determined by the fraction of time
free drug exceeds MIC (f%T>MIC) with the target value
of about 70% suggested for immunosuppressed adults and
potentially for neonates [15].
The PK of meropenem in neonates has been described
in three studies [16-18] but firm dosing recommenda-
tions have not yet been made. By using Monte Carlo
simulations (MCS) two studies [16,18] concluded that for
most microorganisms a dose of 10 mg/kg or 20 mg/kg
given twice or three times a day, depending on the gesta-
tional (GA) and postnatal age (PNA), is sufficient since
>90% of treated neonates will achieve PK/PD target
attainment. One possible short-coming of the simulation
approach taken by Bradley et al [18] was that MIC values
were randomly allocated to simulated patients, thereby
assuming MICs were known a priori, and many of the
allocated MIC values were likely well below the accepted
breakpoints for sensitivity. When designing dosing regi-
mens, MIC is not known in advance and it is therefore
preferable to recommend doses that will cover all organ-
isms up to the sensitivity breakpoint which is usually
2 mg/L for meropenem (http://www.eucast.org). This
approach was taken by van den Anker et al. [16] and in
fact both authors emphasized that higher doses and 4-
hour infusion may be needed for microorganisms with
increased MIC values, more specifically for Pseudomonas
aeruginosa [16,18]. However, this may not be feasible due
to the instability of meropenem (Summary of Product
Characteristics). Whilst it is recommended that merope-
nem should be given within 1 hour of reconstitution, a
recent study has shown that at a concentration of 4% at
room temperature (≤ 25°C) the degradation will be less
than 10% over 12 hours [19].
The advantage of meropenem over standard of care
might be its wider antibacterial coverage and thus the
use of mono- instead of combination therapy.
Clinical trials in LOS
Despite the fact that a number of clinical studies in neona-
tal sepsis have been conducted previously, several metho-
dological issues and the changing patient population make
their results out of date and not applicable to the present
population affected by LOS. It is remarkable that all 13
randomised controlled trials (RCT) are relatively old, dat-
ing from 1973 to 1992 [20]. With the exception of two
studies, [21,22] data on EOS and LOS were combined and
neonatal and paediatric patients were reported together
[23,24]. The variable proportion of missing outcomes as
well as the small sample sizes in the two trials which
included only LOS patients makes drawing meaningful
conclusions from these studies also difficult. Our proposed
NeoMero1 study is therefore designed to address many of
these gaps in the literature.
Methods and Design
Eligible patients
The study will include patients with confirmed as well
as clinical sepsis (Figure 1). Confirmed sepsis will be
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defined as at least one positive bacterial culture (except
CoNS) from a normally sterile site at baseline together
with an abnormal clinical or laboratory parameter
within the last 24 hours prior to randomisation (as listed
below). Clinical sepsis in patients equal or older than 44
weeks of postmenstrual age is based on the criteria
defined by the International Pediatric Sepsis Consensus
Conference [25]. For patients below 44 weeks of post-
menstrual age, the criteria of clinical sepsis were agreed
at the Expert Meeting on Neonatal and Paediatric Sepsis
on 8 June 2010, EMA London (http://www.ema.europa.
eu/docs/en_GB/document_library/Report/2010/12/
WC500100199.pdf) and consist of a combination of at
least two abnormal clinical and two abnormal laboratory
parameters within the 24 hours prior to randomisation.
The relevant clinical criteria are (1) hyper- or hypother-
mia or temperature instability; (2) reduced urinary out-
put or hypotension or mottled skin or impaired
peripheral perfusion; (3) apnea or increased oxygen or
increased ventilatory support requirement; (4) bradycar-
dia spells or tachycardia or rhythm instability; (5) feed-
ing intolerance or abdominal distension; (6) lethargy or
hypotonia or irritability; (7) skin and subcutaneous
lesions such as petechial rash or sclerema. The relevant
laboratory criteria are: (1) white blood cells count
(WBC) < 4 or > 20 × 109 cells/L; (2) immature to total
neutrophil (I/T) ratio > 0.2; (3) platelet count < 100 ×
109/L; (4) C-reactive protein (CRP) > 15 mg/L or pro-
calcitonin ≥ 2 ng/mL; (5) glucose intolerance when
receiving normal glucose amounts (8-15 g/kg/day) as
expressed by blood glucose values > 180 mg/dL or
hypoglycemia (< 40 mg/dL) confirmed on at least two
occasions; (6) acidosis with base excess (BE) < -10
mmol/L or lactate above 2 mmol/L.
Patients who have received systemic antibiotics for
more than 24 hours (except when judged as treatment
failure), have organisms suspected or known to be resis-
tant to study therapies or are not expected to survive
for more than 3 months due to congenital abnormal-
ities, will be excluded as well as patients with renal fail-
ure or known intolerance or contraindications to the
study medications.
Study treatments
Meropenem dose for this study was set at 20 mg/kg q8h
(q12h for neonates with GA < 32 weeks and PNA <2
weeks) based on the results of a previous PK study [18].
The main question to be addressed was infusion length,
Clinical signs 
suggesting LOS
Corrected age 
≤44 weeks
Corrected age 
>44 weeks
Positive blood 
culture
No or negative 
blood culture
Positive blood 
culture
No or negative 
blood culture
≥1 clinical or 
laboratory 
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≥2 clinical &
≥2  laboratory 
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1 : 1 enrollment to meropenem or SOC
Figure 1 Flowchart of the NeoMero1 study.
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as giving the same dose but varying the infusion length
will change f%T>MIC without affecting the area under
the curve (AUC) and therefore overall exposure [16].
Using PK parameters and their uncertainty from an
ongoing study in the USA [unpublished interim model
kindly provided by Dr EV Capparelli], we performed
simulations to investigate the effect of infusion length
on f%T>MIC using the current EUCAST susceptibility
cut-off for Enterobacteriaceae of 2 mg/L (http://www.
eucast.org). These simulations showed that infusion
times of 0.5, 1 and 2 hours gave 90% of patients with f%
T>MIC of at least 44%, 48%, and 50%, respectively with
a skewed distribution meaning that at least 60% in all
age groups had f%T>MIC of 100% (Figure 2). Clearly
increasing infusion length increased f%T>MIC, but
given concerns over meropenem’s stability and that at
least 44% f%T>MIC was achieved for 90% of patients, a
30 minute infusion was finally recommended.
The two most commonly used antibiotic regimens for
LOS (ampicillin + gentamicin or cefotaxime + gentami-
cin) were selected as SOC knowing that both regimens
cover the vast majority of LOS causing agents and have
been in use for several decades [13]. To minimise the
potential bias of an open label design, each participating
unit will select just one of these two regimens prior to
start of the study and will then use it throughout the
study. The dosages for the comparator agents were
selected as recommended in the BNFC (edition of 2010-
2011; http://www.bnfc.org).
The use of other systemic antibacterials will not be
allowed with the exception of vancomycin and other
suitable antibiotics for the treatment of infections pro-
ven or suspected to be caused by methicillin-resistant
CoNS or Staphylococcus aureus. The use of topical anti-
infectives, systemic antifungals, antivirals, immunglobu-
lins and probiotics is allowed and will be recorded in
the case report form.
Ethical aspects
Since the treatment of LOS is an emergency situation
requiring immediate commencement of antibacterial treat-
ment it will not always be possible to obtain the informed
consent (IC) prior to the first dose of any antibiotic.
Therefore the study will allow the enrolment of patients
who have been given antibiotics for LOS according to the
local guidelines for less than 24 hours. This avoids restrict-
ing the study to the less severe cases where treatment can
be delayed until IC has been signed. For the study analysis
patients will be stratified according to whether or not they
received prior antibiotics.
The study aims to minimise interventions made purely
for study purposes. First, all study antibiotics (including
meropenem) are widely used for the treatment of LOS in
the participating units despite the fact that none of them
is labelled for neonates [26]. Second, few procedures will
be conducted only for study purposes; PK samples,
genetic samples and specific microbiologic tests will pre-
ferably be collected when routine clinical sampling is
done; the collection of stool samples does not cause any
extra distress to the baby/infant. Furthermore, the
amount of blood collected for the PK-study (0.3 ml on a
maximum of 3 times) has proven to be safe for ELBW
babies [27].
The study has been approved by the Ethics Review
Committee University of Tartu (205T-18).
Monitoring of clinical and laboratory parameters
In addition to routine clinical monitoring, patients will be
assessed for specific clinical signs and symptoms and for
laboratory abnormalities at baseline, on Day 3, at the end
of the antibacterial- and study treatment and in patients
with a successful outcome, two days after stopping study
treatments (test of cure visit - TOC). At all time points,
clinical symptoms and laboratory parameters will be
graded and compared with those at baseline. They will be
categorised as improved, stable or worsened according to
prespecified criteria. For monitoring relapses, reinfections,
new infections and late safety issues a Day 28 follow up
visit will be conducted for all patients with a successful
outcome at TOC visit. This follow-up (FU) visit is optional
and may be replaced by a telephone interview if necessary
in patients with treatment failure. An auditory assessment
will also be undertaken at any time up until the FU assess-
ments. Finally, a separate study will invite patients at the
corrected age of 20 to 24 months to neurodevelopmental
and auditory testing if the latter was abnormal in the acute
period.
Microbiological assessments
Microbiological samples will be collected at baseline and
on Day 3 and also whenever clinically indicated; they
will be processed in local microbiology laboratories.
Clinically significant isolates from blood or CSF will be
stored at -80°C and sent for identification and antibac-
terial susceptibility to a central microbiology laboratory
in order to ensure uniformity.
To compare the effect of study antibiotics on colonisa-
tion by antibiotic resistant microorganisms and fungi,
stool samples or perianal swabs will be collected on
admission, at the end of study therapy and at hospital
discharge or the follow up visit (whichever is earliest).
For a combination of techniques such as the detection of
16S ribosomal DNA [28], organism specific PCRs and
microarray techniques [29,30], 0.5 mL of whole blood
will be taken on admission and again on Day 3. Molecu-
lar techniques will be used to improve the detection of
pathogens where conventional bacterial cultures are
negative.
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Selection of optimal time points for PK sampling
Using the previously mentioned interim PK model
parameters and their uncertainty, we undertook an
ED-Optimal design exercise to ascertain when to take
samples given the following scenarios: a small cohort
of full profile subjects with 3 post-dose samples, and
the remaining subjects providing a single PK sample.
Optimal sampling times were found to be 0.5, 7-8 and
12 hours post dose for those dosed 12 hourly and 0.5,
5-6 and 8 hours post-dose for those dosed 8 hourly.
For the single sample subjects, the optimal time was a
trough sample.
Statistical aspects
We opted for an efficacy trial. The superiority of merope-
nem over SOC is mainly expected from its wider cover-
age of responsible pathogens and from its potential use
as monotherapy. We estimate that, in the control arm,
15% of patients will die before the TOC visit and among
those who survive the proportion of failing subjects will
be 25% [4,31]. Thus, the proportion of neonates who will
die or fail therapy in the comparator arm is expected to
be 36.25%. It is hypothesized that in the meropenem arm
the survival will be improved to 90% and the failure rate
will drop to 15% in surviving neonates. Thus, the
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Figure 2 Histograms denoting simulated steady-state T>MIC for subjects receiving infusions of meropenem. Each chart presents
different group of subjects depending on GA and PNA. The T>MIC was calculated based on the EUCAST breakpoints for Enterobacteraciae
which is 2 mg/L. PNA - postnatal age, GA - gestational age; ss - steady state
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expected proportion of neonates who will die or fail ther-
apy should be reduced to 23.5%. Based on these assump-
tions, the required sample size to provide 80% power to
show the superiority of meropenem over SOC, using a
continuity-corrected chi-square test with a two-sided 5%
alpha level, is 220 subjects per arm (NQuery software).
We also anticipate that 15 to 20% of randomised neo-
nates will ultimately have conditions not amenable to
study antibiotics, although fulfilling the initial criteria of
clinical sepsis, and thus decrease the apparent treatment
size effect. Consequently, the sample was conservatively
increased by 25%, thus the total population of the study
will be 275 neonates per study arm.
The primary endpoint is a combination of clinical and
microbiological criteria measured at the TOC visit and
defined to a success (the patients is alive, all baseline
symptoms and laboratory parameters are resolved or
improved so that there is no need to continue antibacter-
ial treatment, the baseline microorganisms are eradicated,
there are no new microorganisms identified and patient
has received allocated treatment for 11 ± 3 days with no
modification) and a failure (all remaining cases).
Primary efficacy analysis will compare success rates in
the two arms in all randomised subjects in an intent to
treat approach. Subsidiary analyses of the primary end-
point by the stratification factors (SOC regimen, timing
of antibiotic therapy initiation) will also be performed in
the full analysis set and the confirmed sepsis subset. Var-
ious secondary analyses including comparison of survival
and relapse rates or new infections by Day 28, clinical
response at Day 3 and end of therapy visits, clinical and
bacteriological response and duration of hospital stay will
also be evaluated.
Discussion
The evidence base for novel anti-infective treatments is
limited in newborns, despite their high-risk status for
infection and their vulnerability to its consequences. To
our best knowledge, this is the first randomised con-
trolled study in neonates and young infants with LOS
conducted in the modern era of neonatal care. Although
it is generally accepted that with antibiotics efficacy data
in paediatric patients may not be needed as it might be
extrapolated from adults, neonates are an exception [32].
It is possible that due to the immaturity of the immune
system, the required PK/PD targets in critically ill neo-
nates differ from those in adults, but we are not aware of
these targets having been established [15].
A major challenge for all studies concerning LOS is the
lack of validated clinical and laboratory criteria in situa-
tions where obtaining blood cultures is difficult, sample
volumes are small, a substantial number of cultures
could be negative or contaminated, and almost all clinical
symptoms are non-specific. While the International
Pediatric Sepsis Consensus Conference criteria [25] could
be used for infants and neonates of postmenstrual age of
44 weeks and above, validated criteria for premature
babies, accounting for the majority of LOS cases, are
almost completely lacking. Modi et al. [33] have devel-
oped a predictive model of 12 predefined clinical criteria
for LOS and suggested that the presence of three or
more clinical symptoms has the best predictive accuracy
for positive blood culture in premature neonates. Adding
increased CRP into the model reduced the accuracy; this
is not surprising as CRP is a late rather than early marker
of infection. Others have shown that laboratory markers
such as a platelet count < 100,000/ml [34], procalcitonin
concentration > 2.3-2.4 ng/ml [35,36] or CRP >10 mg/L
[37] are beyond normal ranges in premature babies. Eva-
luation of clinical symptoms is often subjective and could
potentially introduce additional bias especially in a multi-
center and international setting. So we have agreed on a
combination of at least two clinical symptoms and at
least two laboratory parameters to define clinical sepsis.
We hypothesize that using these criteria the number of
patients not having LOS will be minimised. Fairly similar
criteria for LOS were used by one of the NeoMero Con-
sortium partners in a previous study [38] and were also
agreed by the EMA expert panel in June 2010 (http://
www.ema.europa.eu/docs/en_GB/document_library/
Report/2010/12/WC500100199.pdf).
To describe the PK/PD properties of meropenem, a
population PK (popPK) analysis approach will be used as
this allows a description of the variability in PK para-
meters and their dependence on patient characteristics.
PopPK also allows the pooling of sparse data in many
subjects in order to make predictions of f%T>MIC and
its variability given a model derived from the data; the
use of this technique for antimicrobial studies is increas-
ingly recommended [39]. We have been able to inform
the study design through simulation, in this case to
define infusion length, and optimal PK sampling [40].
We have ensured that maximal information can be
gained from the minimally invasive sampling schedule
that has necessarily been imposed due to resource, logis-
tical and patient characteristics in the proposed study.
Whilst the recommended infusion time of 30 minutes
does not achieve our original target of f%T>MIC of 70%,
it has been suggested that f%T>MIC of 40% is sufficient
for the bactericidal activity of carbapenems in patients
with a functioning immune system [39]. Furthermore,
our simulations present a worst-case scenario, in that
many of the microorganisms we expect to encounter will
have MIC values significantly lower than the EUCAST
breakpoints. Through the use of population PK/PD mod-
elling and MCS, the model created from the extensive
data collected in this study will determine the optimal
dose and infusion duration of meropenem.
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An unresolved issue in neonatal studies, especially when
dealing with patients in critical conditions or requiring
rapid therapeutic interventions, is obtaining written IC.
Several aspects were considered by the NeoMero Consor-
tium. We appreciate that obtaining an IC prior to rando-
misation could be extremely challenging. It is expected
that the vast majority of potential participants will be
severely ill babies and the parents may not be available to
sign the IC straight away. Although not proven in neo-
nates, significant evidence from adult studies supports the
role of immediate appropriate antibacterial treatment in
reducing mortality in severe sepsis or septic shock [41].
Therefore in this study the following options to obtain IC
will be explored in agreement with local regulations and
Ethics Committees’ position. First, written IC for potential
LOS cases will be obtained around the time of the NICU
admission. The downside of this option involves unneces-
sary consent in many patients and a possible change in the
parent’s opinion on participation with the sublimation of
the status from a well-baby to a baby with a potentially life
threatening illness. On the other hand, this procedure
guarantees the parents a longer cooling-off period and
offers more possibilities to seek further information before
signing the consent form. The other option would be to
consent over the phone and ask for signed consent when
parents are next in the hospital. A pragmatic option is
therefore to seek consent at the time of the study proce-
dures where possible but also, in recognition that the
study objectives will not be significantly affected, to obtain
consent even after other antibiotic treatment has been
commenced. None of these strategies is ideal and the pre-
ference will also depend on local requirements. This issue
is not specific to the NeoMero studies and might be one
of the reasons that no studies have been conducted in neo-
natal sepsis over the last 20 years despite the fact that
most antibiotics in neonates are used off-label [26].
We appreciate that the ideal study design would be a
blinded rather than an open label study. However, due to
various antibiotic susceptibilities of pathogens in partici-
pating countries and differences in medical practices, find-
ing a single acceptable comparator regimen appeared too
complicated. Blinding would further be compromised by
the fact that meropenem monotherapy is to be compared
with a combination of comparator agents (ampicillin or
cefotaxime plus gentamicin). A dummy infusion in criti-
cally ill, premature babies might lead to fluid overload and
result in deterioration of the babies’ condition. In an
attempt to minimise potential bias the study sites have to
commit to a specific comparator regimen prior to initia-
tion of the study rather than at the time of randomisation,
as this be influenced by their perception of the severity of
the baby’s illness.
Another controversial issue is the influence of mero-
penem or other broad spectrum antibiotics on the
intestinal microflora. Some studies have suggested that
broad spectrum antibiotics interfere with the develop-
ment of intestinal microflora via outselection of antibio-
tic resistant microorganisms which may persist for
several months [42,43]. Others, however, show that
selection of resistant organisms is not associated with
broad spectrum antibiotics but rather with the duration
of the NICU stay and the presence of indwelling cathe-
ters [44,45]. This study provides an opportunity to
assess the influence of different regimens on intestinal
microflora in a controlled setting.
Conclusions
Patients are planned to be randomised from September
2011. The results of the study should provide useful
data on efficacy, safety and PK/PD of meropenem in the
treatment of LOS in neonates and infants up to 90 days
of age. In addition, data about immunogenetics of LOS
as well as the distribution of causative agents and their
antimicrobial resistance patterns will be provided. By
providing a comprehensive list of prospectively collected
data the study will also fulfil an important gap in our
knowledge of neonatal sepsis. The data could then be
used for further dose modelling for other antibiotics and
likely allow more appropriate extrapolations of efficacy
data from adult studies.
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